Tompkins Financial Corp trimmed its stake in shares of Teladoc Health Inc (NYSE:TDOC) by 22.5% in the second quarter, Holdings Channel reports. The fund owned 354 shares of the health services provider’s stock after selling 103 shares during the period. Tompkins Financial Corp’s holdings in Teladoc Health were worth $68,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in TDOC. Capital World Investors lifted its holdings in shares of Teladoc Health by 510.4% in the 1st quarter. Capital World Investors now owns 1,403,845 shares of the health services provider’s stock valued at $217,610,000 after buying an additional 1,173,845 shares during the period. First Trust Advisors LP raised its holdings in Teladoc Health by 1,406.6% during the second quarter. First Trust Advisors LP now owns 1,001,290 shares of the health services provider’s stock worth $191,086,000 after purchasing an additional 934,829 shares during the last quarter. Norges Bank acquired a new position in Teladoc Health during the fourth quarter worth $51,004,000. Fred Alger Management LLC grew its holdings in Teladoc Health by 405.7% in the first quarter. Fred Alger Management LLC now owns 625,931 shares of the health services provider’s stock valued at $97,026,000 after purchasing an additional 502,144 shares during the last quarter. Finally, FDx Advisors Inc. grew its stake in Teladoc Health by 16,754.5% in the 1st quarter. FDx Advisors Inc. now owns 406,531 shares of the health services provider’s stock valued at $575,000 after acquiring an additional 404,119 shares during the last quarter. Institutional investors own 97.14% of the company’s stock.

In other Teladoc Health news, CEO Jason N. Gorevic sold 40,000 shares of Teladoc Health stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $170.26, for a total value of $6,810,400.00. Following the sale, the chief executive officer now owns 711,283 shares of the company’s stock, valued at approximately $121,103,043.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Andrew Turitz sold 2,778 shares of the business’s stock in a transaction that occurred on Friday, June 19th. The shares were sold at an average price of $200.00, for a total value of $555,600.00. Following the completion of the sale, the senior vice president now owns 6,793 shares in the company, valued at approximately $1,358,600. The disclosure for this sale can be found here. Insiders have sold a total of 189,977 shares of company stock worth $36,248,032 in the last three months. 3.42% of the stock is owned by insiders.

A number of brokerages have commented on TDOC. Stephens began coverage on Teladoc Health in a report on Monday, July 6th. They set an “overweight” rating and a $250.00 target price on the stock. Cantor Fitzgerald lifted their target price on shares of Teladoc Health from $165.00 to $210.00 and gave the stock a “neutral” rating in a research note on Thursday. JPMorgan Chase & Co. lifted their price target on Teladoc Health from $240.00 to $266.00 and gave the company an “overweight” rating in a report on Thursday. Credit Suisse Group boosted their target price on shares of Teladoc Health from $165.00 to $225.00 and gave the company a “neutral” rating in a report on Thursday. Finally, ValuEngine cut shares of Teladoc Health from a “buy” rating to a “hold” rating in a research note on Friday, May 1st. Fifteen investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $195.04.

NYSE TDOC opened at $237.63 on Friday. The company has a quick ratio of 6.14, a current ratio of 6.14 and a debt-to-equity ratio of 0.45. Teladoc Health Inc has a 1-year low of $54.58 and a 1-year high of $240.00. The company has a 50 day moving average of $207.13 and a 200-day moving average of $158.76.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, July 29th. The health services provider reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.11). Teladoc Health had a negative return on equity of 10.23% and a negative net margin of 13.22%. The company had revenue of $241.03 million for the quarter, compared to analyst estimates of $220.49 million. During the same quarter in the previous year, the company posted ($0.41) earnings per share. Teladoc Health’s revenue for the quarter was up 85.0% on a year-over-year basis. Sell-side analysts expect that Teladoc Health Inc will post -1.41 earnings per share for the current year.

Teladoc Health Company Profile

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

See Also: Short Selling Stocks and Day Traders

Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health Inc (NYSE:TDOC).

Institutional Ownership by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.